The US Food Drug and Administration adds extensive explanations as well as recommendations in its latest guidance on testing for the presence of cancer-causing nitrosamines in active pharmaceutical ingredient but misses the points the US OTC drug industry recommends.
The “Control of Nitrosamine Impurities in Human Drugs”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?